Investor Relations

Stock price graph
DDXS [OT] : $0.70  + 0.02
Last Updated: 3:59 PM ET on Aug 19, 2014

diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease.

The PLAC Test for Lp-PLA2, diaDexus' flagship product, addresses key unmet medical need, providing actionable information. The PLAC Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States.

diaDexus Corporate Fact Sheet - March 2014 PDF

PLAC Test Fact Sheet - January 2014 PDF

Lp-PLA2 Fact Sheet - January 2014 PDF

Heart Failure Fact Sheet - March 2014 PDF

View all »   RSSRecent Releases

Aug 18, 2014
diaDexus, Inc. Secures $15 Million Debt Financing

Jul 28, 2014
diaDexus, Inc. Reports Second Quarter 2014 Financial Results


©2014 diaDexus, Inc. | diaDexus and PLAC are U.S. Registered Trademarks of diaDexus, Inc.